Literature DB >> 9144372

Differential humoral response against alpha- and beta-linked mannose residues associated with tissue invasion by Candida albicans.

T Jouault1, C Delaunoy, B Sendid, F Ajana, D Poulain.   

Abstract

Candida albicans mannan is the major cell wall antigen that elicits antibodies considered to be of little diagnostic value. It comprises epitopes corresponding to sequences of alpha- and beta-1,2-linked mannose residues. Both types of oligomannosidic epitopes may also be present on the glycosidic portions of other C. albicans molecules, i.e., mannoproteins (MP) (either structural or enzymatic) and glycolipids. The human humoral responses against beta-1,2- and alpha-linked oligomannosides were investigated by C. albicans Western blotting by considering the elective distribution of beta-1,2-oligomannosidic epitopes over a 14- to 18-kDa phospholipomannan (PLM) and the presence of alpha-mannosidic epitopes over heavily glycosylated MP. Western blotting of 51 control sera confirmed the presence of antibodies against C. albicans as a commensal member of the indigenous microflora; an immunoglobulin G (IgG) reactivity linked to enzyme-linked immunosorbent assay mannan signals was found for both PLM (beta-1,2-Man residues) and MP (alpha-Man residues). Despite strong reactivities against mannan and MP, IgG from 21 hospitalized patients with mycological evidence of deep-tissue invasion by C. albicans very significantly failed to react or reacted only faintly with PLM. This downregulation of anti-beta-1,2-oligomannosidic epitopes, associated with tissue invasion by C. albicans, was confirmed in 3 of 4 AIDS patients with extended oroesophageal candidosis. The application of a dissociation procedure proved that the absence of PLM reactivity was not due to the presence of immune complexes. These data provide the first evidence for a qualitative modification of the human antimannan antibody response associated with the C. albicans commensal-pathogenic transition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144372      PMCID: PMC170527          DOI: 10.1128/cdli.4.3.328-333.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  47 in total

1.  Immunoblot analysis of the serological response in systemic candidosis.

Authors:  R C Matthews; J P Burnie; S Tabaqchali
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

2.  Immunoreactivity of neoglycolipids constructed from oligomannosidic residues of the Candida albicans cell wall.

Authors:  C Faille; J C Michalski; G Strecker; D W Mackenzie; D Camus; D Poulain
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

3.  Candida precipitins.

Authors:  W H Chew; T L Theus
Journal:  J Immunol       Date:  1967-02       Impact factor: 5.422

4.  Risk factors for hospital-acquired candidemia. A matched case-control study.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1989-10

5.  Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis.

Authors:  M E Bougnoux; C Hill; D Moissenet; M Feuilhade de Chauvin; M Bonnay; I Vicens-Sprauel; F Pietri; M McNeil; L Kaufman; J Dupouy-Camet
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

Review 6.  Candida cell wall mannan: a polysaccharide with diverse immunologic properties.

Authors:  J E Domer
Journal:  Crit Rev Microbiol       Date:  1989       Impact factor: 7.624

7.  Production and characterization of agglutinating monoclonal antibodies against predominant antigenic factors for Candida albicans.

Authors:  Y Miyakawa; K Kagaya; Y Fukazawa; G Soe
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

8.  Diagnosis of systemic candidiasis by an enzyme-linked dot immunobinding assay for a circulating immunodominant 47-kilodalton antigen.

Authors:  R Matthews; J Burnie
Journal:  J Clin Microbiol       Date:  1988-03       Impact factor: 5.948

9.  Preparation of monoclonal antibodies reactive with beta-1,2-linked oligomannosyl residues in the phosphomannan-protein complex of Candida albicans NIH B-792 strain.

Authors:  M Tojo; N Shibata; M Kobayashi; T Mikami; M Suzuki; S Suzuki
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

10.  Distribution of pathogenic yeasts and humoral antibodies to candida among hospital inpatients.

Authors:  F C Odds; E G Evans
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

View more
  4 in total

1.  Murine model of dextran sulfate sodium-induced colitis reveals Candida glabrata virulence and contribution of β-mannosyltransferases.

Authors:  Samir Jawhara; Estelle Mogensen; François Maggiotto; Chantal Fradin; Aurore Sarazin; Laurent Dubuquoy; Emmanuel Maes; Yann Guérardel; Guilhem Janbon; Daniel Poulain
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

2.  Increased levels of Candida albicans mannan-specific T-cell-derived antigen binding molecules in patients with invasive candidiasis.

Authors:  Jan Kosonen; Arto Rantala; Colin H Little; Päivi Lintu; Pirjo-Riitta Harjamäki; George M Georgiou; Robert E Cone; Johannes Savolainen
Journal:  Clin Vaccine Immunol       Date:  2006-04

3.  Increased sensitivity of mannanemia detection tests by joint detection of alpha- and beta-linked oligomannosides during experimental and human systemic candidiasis.

Authors:  Boualem Sendid; Thierry Jouault; Richard Coudriau; Daniel Camus; Frank Odds; Marc Tabouret; Daniel Poulain
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

4.  Dissection of the anti-Candida albicans mannan immune response using synthetic oligomannosides reveals unique properties of β-1,2 mannotriose protective epitopes.

Authors:  Boualem Sendid; Karine Lecointe; Mayeul Collot; Pierre-Marie Danzé; Sébastien Damiens; Anne-Sophie Drucbert; Chantal Fradin; Jean-Pierre Vilcot; Frédéric Grenouillet; Faustine Dubar; Jérôme de Ruyck; Samir Jawhara; Jean-Maurice Mallet; Daniel Poulain
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.